Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito) today announced that new data on anti-tau antibody etalanetug (development code: E2814) was presented at the 18th Clinical Trials on Alzheimer's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback